Why the study?
Does the CYP2C19 reduced-function allele affect platelet function tests and coagulation/inflammatory biomarkers in stable CAD patients undergoing elective PCI on dual antiplatelet therapy?
Population
104 consecutive Japanese patients with stable CAD and angiographic evidence of ≥75% organic coronary…
Comparison
Carriers of the CYP2C19 reduced-function allele… vs Noncarriers of the CYP2C19 reduced-function…
Design
Cohort
Follow-up
maximum of 6 months (biomarkers measured up to 28 days)
Authors
Loading...
Platelet function testing may identify CYP2C19 carriers on clopidogrel; hypothesis-generating for outcome impact in stable CAD on DAPT.
Does the CYP2C19 reduced-function allele affect platelet function tests and coagulation/inflammatory biomarkers in stable CAD patients undergoing elective PCI on dual antiplatelet therapy?
Platelet function tests, but not coagulation or inflammatory biomarkers, are useful for identifying carriers of the CYP2C19 reduced-function allele and monitoring the efficacy of dual antiplatelet therapy in stable CAD patients undergoing elective PCI.
Kaikita et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: